Semaglutide adọtala mmasị dị ukwuu maka ịdị irè ya na njikwa ibu

Dị ka agonist GLP-1, ọ na-eṅomi mmetụta physiological nke GLP-1 ewepụtara na anụ ahụ.

Na nzaghachi maka oriri glucose, PPG neurons na sistemu ụjọ nke etiti (CNS) na L-cell na eriri afọ na-emepụta ma zoo GLP-1, homonụ na-egbochi eriri afọ.

Mgbe ahapụchara ya, GLP-1 na-arụ ọrụ GLP-1R ndị na-anabata ya na mkpụrụ ndụ β-pancreatic, na-ebute mgbanwe mgbanwe nke metabolic nke insulin secretion na mbelata agụụ.

Ihe nzuzo insulin na-eduga n'ịbelata ọkwa glucose ọbara n'ozuzu ya, mbelata mmepụta glucagon, yana igbochi mwepụta glucose na ụlọ ahịa glycogen imeju. Nke a na-ebute satiety, na-eme ka mmetụta insulin dịkwuo mma, ma na-ebute oke ibu.

Ọgwụ a na-akpali mmepụta insulin n'ụzọ dabere na glucose, si otú a na-ebelata ohere nke hypoglycemia. Na mgbakwunye, ọ nwere mmetụta dị mma na-adịte aka na nlanarị, mmụba, na mmụgharị nke sel β-sel.

Nnyocha na-egosi na semaglutide na-eṅomi mmetụta nke GLP-1 nke ewepụtara na eriri afọ kama site na ụbụrụ. Nke a bụ n'ihi na ọtụtụ ndị na-anabata GLP-1 na ụbụrụ na-edina n'èzí n'ụzọ dị irè nke ọgwụ ndị a na-enye n'usoro. N'agbanyeghị oke ọrụ ya na ụbụrụ GLP-1 ndị na-anabata ya, semaglutide ka na-arụ ọrụ nke ọma n'ibelata oriri na ibu ahụ.

Ọ dị ka imezu nke a site n'ịgbalite netwọkụ neuronal n'ofe sistemu ụjọ nke etiti, ọtụtụ n'ime ha bụ ebumnuche nke abụọ na-anaghị ekwupụta GLP-1 nnabata ozugbo.

Na 2024, ụdị azụmahịa akwadoro nke semaglutide gụnyereOzempic, Rybelsus, naWegovyinjections, niile nke Novo Nordisk mepụtara.